je.st
news
Mercks Investigational 9-valent HPV Vaccine, V503, Prevented 97 Percent of Cervical, Vaginal and Vulvar Pre-cancers Caused by Five Additional HPV Types, in Phase III Study
2013-11-04 13:30:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Immunogenicity non-inferior to GARDASIL for original four HPV types Merck expects to file Biologics License Application with U.S. FDA in 2013 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that in the pivotal Phase III efficacy study, its investigational 9-valent HPV vaccine (V503) prevented approximately 97 percent of cervical, vaginal and vulvar pre-cancers caused by HPV types 31, 33, 45, 52, and 58. Language: English Contact: Media:Pamela Eisele, 908-423-5042orImraan Munshi, 215-652-0059orInvestor:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: in
additional
study
iii
Category:Biotechnology and Pharmaceuticals